Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
2
|
| pubmed:dateCreated |
1997-7-1
|
| pubmed:abstractText |
To compare the efficacy of low and relatively high dosages of recombinant interferon (IFN)-alpha-2a in Japanese patients with chronic hepatitis C, as well as to characterize the type of patients who will respond well to a low-dosage treatment, 88 patients with histologically proven chronic hepatitis C were randomly assigned to two treatment groups; one treated with IFN-alpha-2a 6 MU daily for 2 weeks followed by 6 MU three times weekly for 22 weeks (6-MU group), and another given the same initial treatment followed by 3 MU three times weekly for 22 weeks (3-MU group). The rate of sustained normalization of ALT 6 months after the cessation of treatment was 33% in the 3-MU group and 40% in the 6-MU group (p = 0.64). In addition, there was no difference in elimination of serum HCV-RNA 6 months after the cessation of treatment between the 3-MU group (26%) and 6-MU group (29%). Multivariate stepwise regression analysis revealed that serum HCV-RNA level (p = 0.0035) and platelet count (p = 0.0009) were independent variables useful in predicting a sustained response of ALT. The sustained response rate of ALT in patients with a serum HCV-RNA level less than 10(5) copies/ml and serum platelet level above 15 x 10(4)/microliter was 71%, whereas that in patients with a serum HCV-RNA level above 10(5) copies/ml and serum platelet level less than 15 x 10(4)/microliter was 12%. These results indicate that a high rate of sustained response to IFN therapy can be expected in chronic hepatitis C patients with a low serum level of HCV-RNA and a high level of platelets, even if treated with a low dose of IFN.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Apr
|
| pubmed:issn |
0106-9543
|
| pubmed:author |
pubmed-author:DoiYY,
pubmed-author:FukudaKK,
pubmed-author:HimenoSS,
pubmed-author:IguraTT,
pubmed-author:ImaiYY,
pubmed-author:ItoNN,
pubmed-author:ItoTT,
pubmed-author:KashiharaTT,
pubmed-author:KawakamiFF,
pubmed-author:KawataSS,
pubmed-author:KiriyamaKK,
pubmed-author:KisoSS,
pubmed-author:MaedaHH,
pubmed-author:MatsuzawaYY,
pubmed-author:MinamiYY,
pubmed-author:NishiokaMM,
pubmed-author:NishiuchiMM,
pubmed-author:SekiKK,
pubmed-author:ShinjiYY,
pubmed-author:ShiraiYY,
pubmed-author:TamuraSS,
pubmed-author:YabuuchiII
|
| pubmed:issnType |
Print
|
| pubmed:volume |
17
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
88-92
|
| pubmed:dateRevised |
2011-11-17
|
| pubmed:meshHeading |
pubmed-meshheading:9138278-Antiviral Agents,
pubmed-meshheading:9138278-Chronic Disease,
pubmed-meshheading:9138278-Hepatitis C,
pubmed-meshheading:9138278-Humans,
pubmed-meshheading:9138278-Interferon-alpha,
pubmed-meshheading:9138278-Japan,
pubmed-meshheading:9138278-Recombinant Proteins,
pubmed-meshheading:9138278-Treatment Outcome
|
| pubmed:year |
1997
|
| pubmed:articleTitle |
Recombinant interferon-alpha-2a for treatment of chronic hepatitis C: results of a multicenter randomized controlled dose study.
|
| pubmed:affiliation |
Second Department of Internal Medicine, Osaka University Medical School, Japan.
|
| pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial,
Multicenter Study
|